Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Inks African Distribution Agreement

NEW YORK – Mobidiag today announced that it has signed an exclusive agreement with Pro Med Diagnostics for the distribution of its Amplidiag and Novodiag products in African countries, including South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya, and Uganda.

Tuomas Tenkanen, CEO of Mobidiag, said in a statement that Africa "represents a fast growing market for diagnostic products with enormous growth potential."

Mobidiag is focused on continuing to develop its distributor network as part of its strategy to make its "IVD tests and instruments accessible to customers in centralized and decentralized settings around the world," he said, adding that Pro Med Diagnostics has a "strong background in molecular diagnostics and an extensive customer network."

Espoo, Finland-based Mobidiag markets its Amplidiag and Novodiag molecular diagnostic systems and assays used for the detection of infectious diseases and to address the spread of antimicrobial resistance by rapid detection of pathogens and potential resistance to antibiotics.

The Novodiag automated, cartridge-based system uses real-time PCR and microarray technology to detect infectious diseases and antibiotic resistance, delivering results in approximately one hour. The Amplidiag automated system does batch nucleic acid extraction and PCR plate setup from stool samples.

In June, Mobidiag announced that it has launched a joint venture with Autobio Diagnostics, a leading Chinese clinical diagnostics company, to commercialize its Novodiag system and infectious disease assays in China.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.